compounded semaglutide ban FDA on GLP-1 Drugs: What to Know Compounded "semaglutide" is not FDA-approved

Currently, higher doses of subcutaneous semaglutide (once weekly at 7.2mg) are being evaluated in phase III clinical trials

Its July 17 guidance on compounding semaglutide and tirzepatide is clear and practical, aligning with FDAs enforcement discretion timelines and providing detailed FAQs that address real-world scenarios faced by pharmacies and outsourcing facilities

It helps the body release insulin in response to food, but it also seems to make fat tissue more efficient at storing energy in the right places rather than around the liver or the abdomen

Tirzepatide (or Mounjaro) is currently being researched as an oral formulation and may be available soon